Ernexa Therapeutics (ERNA) Operating Income (2016 - 2025)
Historic Operating Income for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$2.0 million.
- Ernexa Therapeutics' Operating Income rose 1177.51% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.9 million, marking a year-over-year increase of 4706.54%. This contributed to the annual value of -$15.7 million for FY2024, which is 2583.87% up from last year.
- Per Ernexa Therapeutics' latest filing, its Operating Income stood at -$2.0 million for Q3 2025, which was up 1177.51% from -$2.5 million recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' Operating Income ranged from a high of -$2.0 million in Q3 2025 and a low of -$86.3 million during Q3 2021
- Its 5-year average for Operating Income is -$10.1 million, with a median of -$5.3 million in 2023.
- In the last 5 years, Ernexa Therapeutics' Operating Income plummeted by 598434.41% in 2021 and then surged by 9037.51% in 2022.
- Over the past 5 years, Ernexa Therapeutics' Operating Income (Quarter) stood at -$86.3 million in 2021, then soared by 94.51% to -$4.7 million in 2022, then decreased by 21.7% to -$5.8 million in 2023, then surged by 53.22% to -$2.7 million in 2024, then increased by 26.1% to -$2.0 million in 2025.
- Its Operating Income stands at -$2.0 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$2.7 million for Q1 2025.